Ranibizumab outperforms laser in improving diabetic macular edema

08/26/2013 | MedPage Today (free registration)

Data on diabetic macular edema patients showed 49.1% of those on ranibizumab monotherapy attained at least a 5-point improvement in National Eye Institute Visual Functioning Questionnaire 25 composite scores after 12 months, compared with 42.7% of those on ranibizumab plus laser therapy and 30.6% of those on laser-only treatment. However, further analysis is required to determine whether the drug's benefits will be sustained during the three-year study period, researchers reported in JAMA Opthalmology.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD